Research Information For Scientists

Managing Type 2 Diabetes: Implementing Practical Strategies, the case of William

Activity Description

CME Release Date: March 23, 2010
CME Expiration Date: March 23, 2011

This Internet enduring material activity was developed from transcripts and slides from the audio CDs titled Managing Type 2 Diabetes: Implementing Practical Strategies.

This activity is supported by an educational grant from Takeda Pharmaceuticals North America, Inc.

Statement of Need

The evolution of treatments for type 2 diabetes over the last decade has brought us to a new era in the treatment of diabetes, resulting in the mandate that clinicians who treat people with diabetes maintain an updated understanding of the rapidly-changing therapeutic paradigm for this condition. Recent evidence suggests a gap in the knowledge and skill levels of many primary care providers in achieving recommended treatment goals for their patients. Guidelines for managing diabetes are well established, but many patients are not treated effectively due to a multitude of patient, provider, and healthcare delivery systems obstacles. As a result, we are faced with a paradigm of treatment that is less than ideal and the advancement of therapeutic interventions occurs much later than is ideal, preventing or delaying achievement of recommended goals.

In this patient visit simulation, the faculty is diagnosing and treating William, a patient with long-standing type 2 diabetes. In a series of three visits, the faculty will review his chart and lab findings, conduct workups and decide on treatment.

Target Audience

The target audience is primary care providers (MDs, DOs, NPs, PAs) and diabetologists.

Learning Objectives

Participants will be provided with clinically relevant, evidence-based information. Upon completion of this activity, participants should be able to:

  • Explain the natural history of type 2 diabetes including the evolution of insulin resistance and insulin secretory decline as key factors in the clinical progression of the disease
  • Recognize role of the incretin system in normal physiology and in the pathophysiology and treatment of type 2 diabetes
  • Describe process of selecting and advancing treatment regimens for type 2 diabetes in the outpatient setting that balance physiologic needs with individualized self-care considerations
  • List common obstacles to treatment advancement, including patient-based issues such as weight management issues, culture and self-care abilities, and clinician-based issues (such as office system inadequacy) that can contribute to therapeutic inertia
  • Choose appropriate tests and data collection to assist in the diagnosis of a patient with diabetes who is not at goal
  • Interpret test results, including lab values and glucose patterns, and analyze consulting reports from other clinicians, such as dietitians, diabetes educators, cardiologists, and ophthalmologists
  • Develop and implement office-based systems to manage treatment and facilitate therapeutic advancement

Faculty and Disclosures

Robert Heinig, MD
Clinical Professor of Medicine, University of Rochester Medical School
Chief of Endocrinology, Rochester General Hospital
Rochester, NY

Disclosure: Dr. Heinig is on the speakers bureau for Abbott Laboratories, Amylin Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc, sanofi-aventis U.S. LLC, and Takeda Pharmaceuticals North America, Inc.; is a consultant for Merck & Co., Inc.; and receives grant/research support from and is on the speakers bureau for Pfizer Inc.

Kenneth Snow, MD
Assistant Professor of Clinical Medicine, Harvard Medical School
Senior Physician, Adult Diabetes Section
Joslin Diabetes Center
Boston, MA

Disclosure: Dr. Snow has no relevant financial relationships.

Planning Committee:

Enrique Caballero, MD
Director, Medical Affairs, Professional Education
Director, Latino Diabetes Initiative
Joslin Diabetes Center

Disclosure: Dr. Caballero is a consultant and on the speakers bureau for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc, sanofi-aventis U.S. LLC, and Takeda Pharmaceuticals North America, Inc.

Richard S. Beaser, MD
Medical Executive Director, Professional Education
Joslin Diabetes Center

Disclosure: Dr. Beaser is on the academic advisory board for AstraZeneca Pharmaceuticals LP and Bristol-Myers Squibb Company.

Julie A. Brown, Director
Professional Education
Joslin Diabetes Center

Disclosure: Ms. Brown has no relevant financial interests.

James Neighbours, Med
Assistant Director, Education Technology Services
Professional Education
Joslin Diabetes Center

Disclosure: Mr. Neighbours has no relevant financial relationships.

Accreditation and Designation of Credit

The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Joslin Diabetes Center designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This CME activity was planned and produced in accordance with ACCME Essentials.

Participants not eligible for continuing medical education credit will receive a certificate of participation.

Computer Requirements

Credit Instructions

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of the activity.
  2. Read the text and view the slides.
  3. Complete the posttest and evaluation.
  4. Physicians who receive a grade of 70% or better on the posttest and who complete the evaluation will receive immediate CME credit.
  5. All other participants who receive a grade of 70% or better on the posttest and who complete the evaluation will receive a certificate of participation.

Questions About This Activity

For questions regarding the content of this activity, contact the accredited provider for this CME activity:cme@joslin.harvard.edu

Register Now